| Old Articles: <Older 45341-45350 Newer> |
|---|
 |
The Motley Fool
November 11, 2010
Brian Orelli |
ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial.   |
The Motley Fool
November 11, 2010
Travis Hoium |
This Chinese Stock Is in a Rut R&D isn't bringing a turnaround for American Oriental Bioengineering. |
The Motley Fool
November 11, 2010
Andrew Bond |
Klarman Finds Opportunities Scarce Seth Klarman's view on the market should give investors pause. |
The Motley Fool
November 11, 2010
Seth Jayson |
Are SanDisk's Earnings Worse Than They Look? With questionable cash flows amounting to only -3.6% of operating cash flow, SanDisk's cash flows look clean. |
The Motley Fool
November 11, 2010
Travis Hoium |
Darling International Shares Plunged Then Popped: What You Need to Know Darling International shares were all over the place today after the company reported earnings. |
The Motley Fool
November 11, 2010
Brian Orelli |
Moderate Results, Moderate Rally for Dendreon Sometimes good enough really is good enough. |
The Motley Fool
November 11, 2010
Jordan DiPietro |
Where Will Sirius Be in One Year? Can Sirius XM keep going up? |
The Motley Fool
November 11, 2010
Tim Beyers |
One Stock Against the Wind Take a closer look at the insider action at Windstream. |
The Motley Fool
November 11, 2010
Jeremy Phillips |
Introducing My 3 Favorite American Stocks America's long-term prospects are as strong as ever, and in the next five minutes I'm going to prove it to you. |
The Motley Fool
November 11, 2010
Jason Moser |
This Party Is Just Getting Started A look at Activision Blizzard's games, their performance, and the company's future. |
| <Older 45341-45350 Newer> Return to current articles. |
